Skip to main content

Featured

Wall Street Pauses as Fed Meeting Looms: Futures Hold Steady

U.S. stock futures were little changed on Tuesday as investors awaited the start of the Federal Reserve’s final policy meeting of the year. The Dow Jones Industrial Average, S&P 500, and Nasdaq futures all hovered near flat, reflecting a cautious mood across Wall Street. The Fed is widely expected to keep interest rates unchanged, but traders are focused on Chair Jerome Powell’s comments and the central bank’s updated economic projections. Markets are looking for clues on when rate cuts might begin in 2024, with inflation cooling but still above the Fed’s long-term target. Recent gains in equities have been fueled by optimism that the Fed’s tightening cycle is over, yet uncertainty remains about how quickly monetary policy will shift toward easing. Until then, investors appear content to hold their positions, waiting for clearer signals from the Fed before making bold moves.
Post a Comment
Read more

article

Labels

Pharmacare in Canada: A Dream or a Reality?

 


The fate of Canada's pharmacare plan is uncertain as the federal government faces challenges in implementing a universal drug coverage program, even if a bill to create one passes in Parliament. Bill C-213, the Canada Pharmacare Act, aims to establish a national framework for pharmacare that would ensure all Canadians have access to prescription drugs based on their medical needs, not their ability to pay. 

However, the bill does not specify how the program would be funded, administered or negotiated with the provinces and territories, leaving many questions unanswered about the feasibility and cost-effectiveness of pharmacare. Some experts and stakeholders have expressed doubts about whether Ottawa has the political will, the constitutional authority and the fiscal capacity to deliver on its promise of pharmacare, especially in the wake of the COVID-19 pandemic that has strained the health care system and the public purse.

Labels:

Comments

Post a Comment